Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Oliver Illini, Felix Carl Saalfeld, Petros Christopoulos, Michaël Duruisseaux, Anders Vikström, Nir Peled, Ingel Demedts, Elizabeth Dudnik, Anna Eisert, Sayed M S Hashemi, Urska Janzic, Waleed Kian, Katja Mohorcic, Saara Mohammed, Maria Silvoniemi, Sacha I Rothschild, Christian Schulz, Claas Wesseler, Alfredo Addeo, Karin Armster, Malinda Itchins, Marija Ivanović, Diego Kauffmann-Guerrero, Jussi Koivunen, Jonas Kuon, Nick Pavlakis, Berber Piet, Martin Sebastian, Janna-Lisa Velthaus-Rusik, Luciano Wannesson, Marcel Wiesweg, Robert Wurm, Corinna Albers-Leischner, Daniela E Aust, Melanie Janning, Hannah Fabikan, Sylvia Herold, Anna Klimova, Sonja Loges, Yana Sharapova, Maret Schütz, Christoph Weinlinger, Arschang Valipour, Tobias Raphael Overbeck, Frank Griesinger, Marko Jakopovic, Maximilian J Hochmair, Martin Wermke
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We performed an international, real-world safety and efficacy analysis on patients with EGFR Ex20-positive NSCLC enrolled in a mobocertinib early access program. We explored the mechanisms of resistance by analyzing postprogression biopsies, as well as cross-resistance to amivantamab...
April 3, 2024: International Journal of Molecular Sciences
#22
JOURNAL ARTICLE
Silvana Talisa Wijaya, Natalie Yl Ngoi, Jerold Wz Loh, Tuan Zea Tan, Diana Lim, Irfan Sagir Khan, Yee Liang Thian, Alexa Lai, Bertrand Wl Ang, Pearl Tong, Joseph Ng, Jeffrey Jh Low, Arunachalam Ilancheran, Siew Eng Lim, Yi Wan Lim, David Sp Tan
OBJECTIVE: Ovarian clear cell carcinoma (OCCC) is associated with chemoresistance. Limited data exists regarding the efficacy of targeted therapies such as immune checkpoint inhibitors (ICI) and bevacizumab, and the role of secondary cytoreductive surgery (SCS). METHODS: We retrospectively analyzed genomic features and treatment outcomes of 172 OCCC patients treated at our institution from January 2000 to May 2022. Next-generation sequencing (NGS) was performed where sufficient archival tissue was available...
March 29, 2024: Journal of Gynecologic Oncology
#23
JOURNAL ARTICLE
Fara Hassan, Jiang Huai Wang, Donal Peter O'Leary, Mark Corrigan, Henry Paul Redmond
BACKGROUND: Circulating tumour DNA (ctDNA), contains tumour-specific gene mutation in blood circulation and could aid in postoperative risk stratification of non-metastatic breast cancer. In this study, we investigated the feasibility of detecting PIK3CA gene mutations in ctDNA in the preoperative (preop) and postoperative period (postop), and its prognostic significance in patients with breast cancer. METHODS: A cohort of patients with breast cancer undergoing curative surgery with available blood samples preoperatively and postoperatively (Post op) at either Post op time period; week 1-2, week 3-4 or weeks 5-12 were enrolled...
March 5, 2024: Surgical Oncology
#24
JOURNAL ARTICLE
Rishi R Lulla, Allen Buxton, Mark D Krailo, Margot A Lazow, Daniel R Boue, James L Leach, Tong Lin, James I Geller, Shiva Senthil Kumar, Marina N Nikiforova, Uma Chandran, Sachin S Jogal, Marvin D Nelson, Arzu Onar-Thomas, Daphne A Haas-Kogan, Kenneth J Cohen, Mark W Kieran, Amar Gajjar, Rachid Drissi, Ian F Pollack, Maryam Fouladi
BACKGROUND: Outcomes for children with high-grade gliomas (HGG) remain poor. This multicenter phase II trial evaluated whether concurrent use of vorinostat or bevacizumab with focal radiotherapy (RT) improved 1-year event-free survival (EFS) compared to temozolomide in children with newly diagnosed HGG who received maintenance temozolomide and bevacizumab. METHODS: Patients ≥ 3 and < 22 years with localized, non-brainstem HGG were randomized to receive RT (dose 54-59...
2024: Neuro-oncology advances
#25
JOURNAL ARTICLE
Valentina Angerilli, Alessandro Vanoli, Giulia Celin, Carlotta Ceccon, Jessica Gasparello, Marianna Sabbadin, Giuseppe De Lisi, Michele Paudice, Marco Vincenzo Lenti, Laura Rovedatti, Antonio Di Sabatino, Francesca Bazzocchi, Sara Lonardi, Edoardo Savarino, Claudio Luchini, Paola Parente, Federica Grillo, Luca Mastracci, Matteo Fassan
Patients with autoimmune gastritis (AIG) have a 13-fold risk of developing type-1 neuroendocrine tumors, whereas the risk for gastric adenocarcinoma is still uncertain. Here we describe the clinicopathological and molecular features of a series of gastric carcinomas (GC) arising in the context of AIG. A total of 26 AIG-associated GC specimens were collected from four Italian Institutions. Immunohistochemistry for MUC1, MUC2, MUC5AC, MUC6, CDX2, HER2, PD-L1, CLDN18, Mismatch Repair (MMR) proteins, and p53 and EBER in situ hybridization were performed...
April 6, 2024: Modern Pathology
#26
JOURNAL ARTICLE
Eliya Shachar, Ari Raphael, Uriel Katz, Rivka Kessner, Shlomit Strulov Shachar
BACKGROUND: Body composition has emerged as an important prognostic factor in patients treated with cancer. Severe depletion of skeletal muscle, sarcopenia, has been associated with poor performance status and worse oncological outcomes. We studied patients with metastatic breast cancer receiving alpelisib, to determine if sarcopenia and additional body composition measures accounting for muscle and adiposity are associated with toxicity. METHODS: A retrospective observational analysis was conducted, including 38 women with metastatic breast cancer and a PIK3CA mutation, treated with alpelisib as advanced line of therapy...
April 7, 2024: Breast Cancer Research and Treatment
#27
JOURNAL ARTICLE
Katey S S Enfield, Emma Colliver, Claudia S Y Lee, Alastair Magness, David A Moore, Monica Sivakumar, Kristiana Grigoriadis, Oriol Pich, Takahiro Karasaki, Philip S Hobson, Dina Levi, Selvaraju Veeriah, Clare Puttick, Emma L Nye, Mary Green, Krijn K Dijkstra, Masako Shimato, Ayse U Akarca, Teresa Marafioti, Roberto Salgado, Allan Hackshaw, TRACERx Consortium, Mariam Jamal-Hanjani, Febe van Maldegem, Nicholas McGranahan, Benjamin Glass, Hanna Pulaski, Eric Walk, James L Reading, Sergio A Quezada, Crispin T Hiley, Julian Downward, Erik Sahai, Charles Swanton, Mihaela Angelova
Understanding the role of the tumour microenvironment (TME) in lung cancer is critical to improving patient outcome. We identified four histology-independent archetype TMEs in treatment-naive early-stage lung cancer using imaging mass cytometry in the TRACERx study (n=81 patients/198 samples/2.3million cells). In immune-hot adenocarcinomas, spatial niches of T cells and macrophages increased with clonal neoantigen burden, whereas such an increase was observed for niches of plasma and B cells in immune-excluded squamous cell carcinomas (LUSC)...
April 6, 2024: Cancer Discovery
#28
JOURNAL ARTICLE
Yoo-Na Kim, Yun Soo Chung, Eunhyang Park, Seung Tae Lee, Jung-Yun Lee
Human epidermal growth factor receptor-2 (HER2)-targeting drugs are increasingly being incorporated into therapeutic paradigms for non-breast cancers, yet studies on HER2 expression in ovarian cancer (OC) are inadequate. Here, we studied the HER2 status and dynamic changes in OC by reviewing the records of patients who underwent HER2 testing at a single institution. Clinical parameters, including histology, BRCA status, and immunohistochemistry (IHC), were evaluated alongside HER2 expression, timing, and anatomical location...
April 5, 2024: Scientific Reports
#29
JOURNAL ARTICLE
Xiu-Juan Qin, Wen-Jie Hu, Xian-Jin Xu
AIM: of the study: This study used network pharmacology and the Gene Expression Omnibus (GEO) database to investigate the therapeutic effects of Corbrin capsules on acute kidney injury (AKI)-COVID-19 (coronavirus disease 2019). MATERIALS AND METHODS: The active constituents and specific molecular targets of Corbrin capsules were obtained from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) and Swiss Target Prediction databases. The targets related to AKI and COVID-19 disease were obtained from the Online Mendelian Inheritance in Man (OMIM), GeneCards, and GEO databases...
April 3, 2024: Gene
#30
JOURNAL ARTICLE
Clement Chung, Godsfavour Umoru
BACKGROUND: Since the publication of the original work in 2014, significant progress has been made in the characterization of genomic alterations that drive oncogenic addiction of nonsmall cell lung cancer (NSCLC) and how the immune system can leverage non-oncogenic pathways to modulate therapeutic outcomes. This update evaluates and validates the recent and emerging data for prognostic and predictive biomarkers with therapeutic targets in NSCLC. DATA SOURCES: We performed a literature search from January 2015 to October 2023 using the keywords non-small cell lung cancer , clinical practice guidelines , gene mutations , genomic assay , immune cancer therapy , circulating tumor DNA , predictive and prognostic biomarkers , and targeted therapies ...
April 5, 2024: Journal of Oncology Pharmacy Practice
#31
JOURNAL ARTICLE
Nurul Wafiqah Saipol Bahrin, Siti Nur Idayu Matusin, Aklimah Mustapa, Lu Zen Huat, Sriyani Perera, Mas Rina Wati Haji Abdul Hamid
BACKGROUND: Breast cancer incidence has been on the rise significantly in the Asian population, occurring at an earlier age and a later stage. The potential predictive value of molecular subtypes, biomarkers, and genetic variations has not been deeply explored in the Asian population. This study evaluated the effect of molecular subtype classification and the presence or absence of biomarkers and genetic variations on pathological complete response (pCR) after neoadjuvant treatment in Asian breast cancer patients...
April 4, 2024: Systematic Reviews
#32
JOURNAL ARTICLE
Hitomi Hoshino, Daisuke Inoue, Akiko Shinagawa, Hisato Yoshida, Shohei Shigeto, Kazuyuki Matsuda, Tomoya O Akama, Yoshio Yoshida, Motohiro Kobayashi
A human ovarian clear cell carcinoma cell line was established from a 46-year-old Japanese woman. That line, designated MTC-22, has proliferated continuously for over 6 months in conventional RPMI 1640 medium supplemented with 10% foetal bovine serum and has been passaged over 50 times. MTC-22 doubling-time is ~ 18 h, which is much shorter than most ovarian clear cell carcinoma lines reported to date. Morphologically, MTC-22 cells exhibit polygonal shapes and proliferate to form a monolayer in a jigsaw puzzle-like arrangement without contact inhibition...
April 4, 2024: Human Cell
#33
REVIEW
Alexa J Luboff, David L DeRemer
OBJECTIVE: To review the pharmacology, efficacy, and safety of capivasertib for the treatment of adults with hormone receptor-positive, HER2-negative (HR+/HER2-) locally advanced or metastatic breast cancer with 1 or more PIK3CA/AKT1/PTEN alterations. DATA SOURCES: A literature search was conducted using PubMed and MEDLINE databases, published abstracts, and studies from ClinicalTrials.gov between 2003 and February 2024. Keywords included capivasertib, AZD5363, PI3K/AKT/mTOR pathway, and breast cancer...
April 2, 2024: Annals of Pharmacotherapy
#34
JOURNAL ARTICLE
Ziwei Wang, Shen Chen, Yuzhi Guo, Rui Zhang, Qi Zhang, Xinhang Jiang, Miao Li, Yue Jiang, Lizhu Ye, Xiaoyu Guo, Chuang Li, Guangtong Zhang, Daochuan Li, Liping Chen, Wen Chen
The high incidence of colorectal cancer (CRC) is closely associated with environmental pollutant exposure. To identify potential intestinal carcinogens, we developed a cell transformation assay (CTA) using mouse adult stem cell-derived intestinal organoids (mASC-IOs) and assessed the transformation potential on 14 representative chemicals, including Cd, iPb, Cr-VI, iAs-III, Zn, Cu, PFOS, BPA, MEHP, AOM, DMH, MNNG, aspirin, and metformin. We optimized the experimental protocol based on cytotoxicity, amplification, and colony formation of chemical-treated mASC-IOs...
April 2, 2024: Archives of Toxicology
#35
MULTICENTER STUDY
Hélène Salaün, Lounes Djerroudi, Laura Haik, Anne Schnitzler, Guillaume Bataillon, Gabrielle Deniziaut, Ivan Bièche, Anne Vincent-Salomon, Marc Debled, Paul Cottu
Everolimus is widely used in patients with advanced ER-positive, HER2-negative breast cancer. We looked at alterations in the PIK3CA/AKT/mTOR pathway in a multicenter cohort as potential biomarkers of efficacy. Patients with advanced ER-positive, HER2-negative breast cancer treated with everolimus and endocrine therapy between 2012 and 2014 in two cancer centers were included. Targeted sequencing examined mutations in PIK3CA, ESR1, and AKT1 genes. An immunochemical analysis was conducted to evaluate expression of PTEN, INPP4B, STK11, p4EBP1, and pS6...
May 2024: Journal of Pathology. Clinical Research
#36
JOURNAL ARTICLE
Omar M Salih, Mahmoud A Al-Sha'er, Haneen A Basheer
Sixteen novel 2-aminobenzothiazole compounds with different amines or substituted piperazine moieties were designed, synthesized, and tested using various methods. Potential interactions were assessed by docking new compounds in the adenosine triphosphate (ATP) binding domain of the PI3Kγ enzyme (PDB code: 7JWE) by nucleophilic substitution or solvent-free/neat fusion for docked compound synthesis. Final 2-aminobenzothiazole compounds were characterized by direct probe gas chromatography-mass spectrometry (GC-MS), proton (1 H-NMR), carbon-13 (13 C-NMR), and attenuated total reflectance-infrared Fourier transform infrared (ATR FT-IR)...
March 26, 2024: ACS Omega
#37
Marco Matejcic, Jamie K Teer, Hannah J Hoehn, Diana B Diaz, Kritika Shankar, Jun Gong, Nathalie T Nguyen, Nicole Lorona, Domenico Coppola, Clifton Fulmer, Ozlen Saglam, Kun Jiang, Douglas Cress, Teresita Muñoz-Antonia, Idhaliz Flores, Edna Gordian, José A Oliveras Torres, Seth I Felder, Julian A Sanchez, Jason Fleming, Erin M Siegel, Jennifer A Freedman, Julie Dutil, Mariana C Stern, Brooke L Fridley, Jane C Figueiredo, Stephanie L Schmit
UNLABELLED: Ancestrally diverse and admixed populations, including the Hispanic/Latino/a/x/e community, are underrepresented in cancer genetic and genomic studies. Leveraging the Latino Colorectal Cancer Consortium, we analyzed whole exome sequencing data on tumor/normal pairs from 718 individuals with colorectal cancer (128 Latino, 469 non-Latino) to map somatic mutational features by ethnicity and genetic ancestry. Global proportions of African, East Asian, European, and Native American ancestries were estimated using ADMIXTURE...
March 15, 2024: medRxiv
#38
JOURNAL ARTICLE
Neslihan Kayraklioglu, Bradley A Stohr, Emily Chan
CONTEXT.—: Human papillomavirus (HPV) is a well-known cause of squamous cell carcinomas of anogenital and oropharyngeal regions, where treatment strategies and prognosis depend on HPV status. The significance of HPV status in tumors arising along the urinary tract is not well established. OBJECTIVE.—: To provide detailed clinical, morphologic, immunohistochemical, and molecular analysis of HPV+ urinary tract carcinomas (UTCs). DESIGN...
April 1, 2024: Archives of Pathology & Laboratory Medicine
#39
JOURNAL ARTICLE
Zi-Yi Fu, Ying Huang, Le-Shen Lian, Hui-Ting Huang, Shao-Feng Zhan, Yan Cai, Jun-Xiong Li, Xiao-Hong Liu
BACKGROUND: The objective of this research was to investigate how the combination of semen coicis extract and PD-1 inhibitors can potentially work together to enhance the anti-tumor effects, with a focus on understanding the underlying mechanism. METHODS: We obtained the active components and specific targets of semen coicis in the treatment of NSCLC from various databases, namely TCMSP, GeneCard, and OMIM. By utilizing the STRING database and Cytoscape software, we established a protein interaction network (PPI) for the active ingredient of semen coicis and the target genes related to NSCLC...
March 30, 2024: Clinical & Translational Oncology
#40
JOURNAL ARTICLE
Roberto J Alcazar-Felix, Abhinav Srinath, Stephanie Hage, Akash Bindal, Andrew Ressler, Peter Pytel, Sammy Allaw, Romuald Girard, Douglas A Marchuk, Issam A Awad, Sean P Polster
BACKGROUND: Radiation treatment for diseases of the brain can result in hemorrhagic adverse radiation effects. The underlying pathologic substrate of brain bleeding after irradiation has not been elucidated, nor potential associations with induced somatic mutations. METHODS: We retrospectively reviewed our department's pathology database over 5 years and identified 5 biopsy specimens (4 patients) for hemorrhagic lesions after brain irradiation. Tissues with active malignancy were excluded...
March 27, 2024: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
